bluebird bio has rebranded as Genetix Biotherapeutics, returning to our foundational roots and renewing our commitment to delivering transformative genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These first-in-class, one-time administered therapies treat the underlying cause of disease and can offer significant and lasting benefits to patients.
On June 2nd, 2025, we marked a pivotal moment: announcing a newly appointed leadership team and our transition to a privately held company. We are now stronger, both financially and operationally, and better positioned to harness our decades of scientific innovation and extensive clinical data from hundreds of treated patients to unlock the full potential of our life-changing genetic therapies.
